By Scott Kanowsky Investing.com -- Shares in Altimmune, Inc. (NASDAQ:ALT) slumped by more than 54% on Tuesday, touching their lowest level since June, as concerns grew over the safety of...
On market days like Wednesday, the Club is considering the impact that concerns about Credit Suisse's health have on our holdings.
By Liz Moyer Investing.com -- Stocks rallied on Tuesday after inflation data stoked hopes the Federal Reserve would be less aggressive with interest rates when it meets next week and bank...
Novo Nordisk A/S (NYSE: NVO) is lowering the U.S. list prices of some insulin products by up to 75%. Products include prefilled pens and vials of basal (long-acting), bolus (short-acting),...
Tuesday's top analyst upgrades and downgrades included Ally Financial, Amgen, Baidu, Bilibili, Bill.com, Coinbase Global, Eli Lilly, GE Healthcare Technologies, JPMorgan Chase, Merck,...
By Davit Kirakosyan Wells Fargo upgraded Amgen (NASDAQ:AMGN) and Eli Lilly (NYSE:LLY) while downgrading Merck (NYSE:MRK). Amgen was upgraded to Overweight from Equal Weight with a price...
By Michael Elkins JPMorgan reiterated an Overweight rating and a $400.00 price target on Eli Lilly and Company (NYSE:LLY) ahead of the upcoming release of the donanemab ph3 data. Analysts...
Alzheimer's drug from Eli Lilly And Co (NYSE: LLY) failed to slow cognitive decline over about 4.5 years of treatment in individuals with amyloid plaque but no clinical symptoms. The...
Eli Lilly and Company (LLY) announced today that solanezumab did not slow the progression of cognitive decline due to Alzheimer's disease (AD) pathology when initiated in individuals with...
The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) investigating a potential new indication to lower blood sugar...
The drugmaker’s plan moves the spotlight to industry middlemen, who face a barrage of investigations.
By Sam Boughedda Jefferies analysts initiated Eli Lilly & Co. (NYSE:LLY) with a Hold rating and $290 price target and Merck & Company Inc (NYSE:MRK) with a Buy rating and $125 price target...
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Verzenio® (abemaciclib), in combination with endocrine...
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
By Liz Moyer Investing.com -- Stocks edged lower on Wednesday to start a new month after ending lower for February. Here are the midday movers for March 1. Novavax Inc (NASDAQ:NVAX)...
By Geoffrey Smith Investing.com -- Eli Lilly (NYSE:LLY) said it will cut the price of its most commonly prescribed diabetes drugs by 70% and cap out-of-pocket costs for patients at $35 a...
Eli Lilly and Company (LLY) today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket...
Eli Lilly And Co (NYSE: LLY) said that all doses of its new diabetes drug Mounjaro (tirzepatide) were now available, with wholesalers having inventory after a two-month-long shortage. Due to...
Singapore, Feb. 20, 2023 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the Global Ataxia Diagnosis and Treatment Market is expected to clock US$...
Retailers CVS Health, Walgreens and Kroger have announced new initiatives to provide clinical trial enrollment and follow-up services in their pharmacy clinics.
By Davit Kirakosyan Evercore ISI downgraded Marriott International (NASDAQ:MAR) to In Line from Outperform with a price target of $180.00 despite the company’s reported solid...
By Yasin Ebrahim Investing.com -- The Dow closed flat Thursday, as investors piled in on tech stocks following a rally in Meta, though weakness in health care and energy weighed on upside...
By Liz Moyer Investing.com -- Stocks were rising on a Meta-fueled tech rally that lifted the Nasdaq more than 3% on Thursday. Here are the midday movers for Feb.2. Meta Platforms Inc...
By Shreyashi Sanyal and Johann M Cherian (Reuters) -Nasdaq futures jumped on Thursday as Meta Platforms (NASDAQ:META) surged on rigorous cost controls, while a dovish message from Federal...
By Geoffrey Smith Investing.com -- Stocks in focus in premarket trading on Thursday, 2nd February. Meta Platforms (NASDAQ:META) stock surged 20% after the social media giant added $40...
By Senad Karaahmetovic Shares of Eli Lilly (NYSE:LLY) are moving lower in pre-market despite the company reporting better-than-expected fourth-quarter results and raising its full-year EPS...
Investing.com - Eli Lilly (NYSE: LLY) reported fourth quarter EPS of $2.09, $0.29 better than the analyst estimate of $1.80. Revenue for the quarter came in at $7.3B versus the consensus...
By Geoffrey Smith Investing.com -- The dollar falls to a nine-month low and Treasury yields ease after the Federal Reserve signals the end is near for the current rate hiking cycle. The...
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about...
By Liz Moyer Investing.com -- Tech stocks were rallying on Friday after better-than-expected subscriber numbers from Netflix and cost-cutting by Google parent Alphabet. Here are the midday...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
